Firebrick Pharma announced that it is re-starting a Phase 3 clinical trial of Nasodine povidone-iodine nasal spray as the 2023 common cold season begins in the Southern Hemisphere. According to the company, the trial, which is taking place in Australia and South Africa, was paused for the summer after having fulfilled half of its recruitment goal during the 2022 cold … [Read more...] about Firebrick Pharma restarts Phase 3 trial of Nasodine nasal spray for the common cold
News
Allermi raises $3.5 million for direct-to-consumer customized nasal spray
US start-up Allermi said that it has raised $3.5 million in a seed round led by Nelstone Ventures for "the world’s first custom approach offered by Allermi that combines and adjusts the doses of multiple clinically-proven medications into one nasal spray bottle to address patients’ specific symptoms." The company says that its nasal spray service is currently … [Read more...] about Allermi raises $3.5 million for direct-to-consumer customized nasal spray
Stevanato Group to supply syringes for Recipharm’s Resyca syringe-based SMIs
The Stevanato Group has announced that it will manufacture pre-fillable glass syringes for Recipharm's Resyca pre-filled syringe soft mist inhalers for the delivery of biologics. According to Stevanato Group, the interior of the Alba glass syringe has a silicone oil-based coating for improved particle release. The Resyca SMI is the product of a 2020 joint … [Read more...] about Stevanato Group to supply syringes for Recipharm’s Resyca syringe-based SMIs
RDD Europe 2023 returns to Antibes
RDD Europe 2023, organized by RDD Online and Aptar Pharma, returns to Antibes, France, May 2-5 at the Palais des Congrès Antipolis. Richard Dalby of RDD Online says that conference center (previously called the Palais des Congrès Antibes) proved popular with attendees at RDD Europe 2015 and 2017, which took place at the same venue. Dalby expects that attendance will … [Read more...] about RDD Europe 2023 returns to Antibes
Phase 2a study of Aridis’s AR-501 inhaled gallium in CF patients meets primary and secondary endpoints
Aridis Pharmaceuticals has announced that a Phase 2a study of the company's AR-501 nebulized gallium in cystic fibrosis patients with P. aeruginosa lung infections met its primary and secondary endpoints, with all 3 dose levels tested being well tolerated. According to Aridis, uptake of AR-501 in the respiratory track was up to 10 times higher than previously reported … [Read more...] about Phase 2a study of Aridis’s AR-501 inhaled gallium in CF patients meets primary and secondary endpoints
ReCode initiates Phase 1 trial of RCT1100 inhaled mRNA therapeutic
ReCode Therapeutics said that it has initiated a Phase 1 clinical trial of its RCT1100 nebulized mRNA-based therapeutic, which the company is developing for the treatment of primary ciliary dyskinesia (PCD) caused by certain genetic mutations. ReCode had announced positive preclinical results for RCT1100 for the treatment of PCD in August 2021. The Phase 1 single … [Read more...] about ReCode initiates Phase 1 trial of RCT1100 inhaled mRNA therapeutic
Lonza Small Molecules adds powder characterization capabilities at Florida facility
The Lonza Small Molecules facility in Tampa, FL, USA has upgraded its powder analysis capabilities, the company said. In May 2022, Lonza announced that it was expanding its dry powder testing facilities in Tampa in order to increase its DPI development capacity. According to Lonza, the Tampa site recently added a Freeman Technologies FT4 universal powder flow … [Read more...] about Lonza Small Molecules adds powder characterization capabilities at Florida facility
Nemera and Nelson Labs announce expanded partnership
Device maker Nemera and Nelson Labs have announced the expansion of an existing partnership, with Nelson Labs performing microbiological and chemical analyses, extractables and leachables testing, and biocompatibility studies for Nemera customers. Nemera is an associate member of the International Pharmaceutical Aerosol Consortium on Regulation & Science … [Read more...] about Nemera and Nelson Labs announce expanded partnership
Bryn Pharma names Sandy Loreaux as CEO
Utuly intranasal epinephrine developer Bryn Pharma has named Sandy Loreaux as CEO, succeeding David Dworaczyk, who will remain with the company as head of R&D, regulatory, and production. Loreaux was most recently US President of Covis Pharma and previously held executive positions at Mallinckrodt, Valeant, and Sanofi-Aventis. Bryn recently announced results … [Read more...] about Bryn Pharma names Sandy Loreaux as CEO
Iliad publishes data from Phase 2b challenge study of BPZE1 intranasal pertussis vaccine
Iliad Biotechnologies announced that it has published data from a Phase 2b challenge study of its BPZE1 live-attenuated intranasal pertussis vaccine and said that the vaccine induced nasal mucosal and serum immune responses, with 90% of participants who received a single dose of BPZE1 protected from colonization following a challenge with attenuated B. pertussis at 3 … [Read more...] about Iliad publishes data from Phase 2b challenge study of BPZE1 intranasal pertussis vaccine